On the basis of these observations, in the present case—where we identified a G-CSF- and IL-6-secreting tumor associated with increased circulating levels of IL-6, PCR, and ferritin, as well as a somatic tumor mutation of the PI3KCA gene, which is present in at least 40% of cervical cancers [70]—we attempted to co-target both the specific mutation driving the tumor growth and the pathways involved in the production of G-CSF and IL-6 by using a monoclonal antibody against PI3KA [71] and a JAKs inhibitor [58,72]; our aim was that such an approach would result in effective treatment. This evidence concerns the gene IL6 and neoplasm.